StockNews.AI
CDT
StockNews.AI
4 hrs

CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy

1. CDT identified a new biological target for AZD1656 through AI methods. 2. Positive pre-clinical data supports drug repurposing strategies for untapped indications. 3. CDT aims to further clinical studies following successful initial findings. 4. A robust patent portfolio underpins new therapeutic pathways for AZD1656. 5. Management emphasizes a successful transition to a lean, data-driven operation model.

6m saved
Insight
Article

FAQ

Why Bullish?

The identification of new applications for AZD1656 significantly enhances its market potential, which could lead to increased investor confidence and higher stock prices. Historical cases, like Gilead's remdesivir, show that drug repositioning can lead to significant market gains.

How important is it?

The findings position CDT favourably in the competitive biotech landscape, though artificial intelligence-driven drug discovery success is still in early phases.

Why Long Term?

The pipeline of further pre-clinical studies indicates a commitment to developing AZD1656, likely creating long-lasting effects on company valuation as results materialize over time.

Related Companies

GILDBMYJNJ
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 26, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announces that it has successfully identified a new biological target and novel therapeutic indication for its lead programme, AZD1656 (and its derivatives), following positive data from pre-clinical studies. This affirms the Company’s decision to pursue an artificial intelligence-led drug repurposing strategy for its portfolio. CDT, in collaboration with Sarborg, has carried out an in-depth analysis of AZD1656, utilizing an algorithmic approach that involves AI-powered disease mapping to identify repurposing opportunities against a database of over 800 diseases signatures. This new approach identified several indications for AZD1656 in therapeutic areas previously not associated with this asset. With a robust patent portfolio already in place, CDT has initiated several pre-clinical studies to explore the potential of AZD1656 in these untapped therapeutic areas. The results of the first of these pre-clinical studies has verified the findings of the algorithmic approach and validated an exciting new biological target for AZD1656. Given the clinical significance of this target, and the potentially highly valuable commercial pathway this could present, CDT now plans to expand on this positive outcome initiating further pre-clinical studies to fully explore the extent of this new finding. “Transitioning our operating model to a lean, disease-agnostic model informed by data-driven insights has now proved successful. CDT has identified novel indications for AZD1656 never previously considered, and the positive results seen in the first of our pre-clinical studies has already proven the effectiveness and potential value of this strategy.” Said Dr. Jo Holland, Chief Scientific Officer of CDT, “We are excited to explore this opportunity for AZD1656 further, to progress the asset to a commercial out-licensing opportunity.” Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT's future results of operations and financial position, CDT's business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavours with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the inability to maintain the listing of CDT's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties to be identified in the proxy statement/prospectus (as amended and supplemented) relating to the business combination completed in September 2023, including those under "Risk Factors" therein, and in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT's control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations. Investors & Media:info@cdtequity.com

Related News